Weight-loss doctor says GLP-1 microdosing lacks evidence and any agreed definition
A physician writing in STAT says patients keep asking about tiny GLP-1 doses, but there is no long-term evidence or standard definition to guide an answer.
Microdosing GLP-1 medications is a popular trend with no legitimate long-term data behind it and no agreed definition of what a microdose is, according to a First Opinion piece published May 29, 2026, in STAT [1].
The author is Jody Dushay, an assistant professor of medicine at Harvard Medical School and an attending endocrinologist at Beth Israel Deaconess Medical Center [1]. She writes that patients ask her about microdosing, that TV and online ads promote it, and that friends speculate about who is doing it [1].
Her conclusion is blunt. "Microdosing GLP-1s is not a thing," she writes. "There are no legitimate long-term data to support it. In fact, there isn't even a single definition of microdosing for weight loss or any other condition" [1].
The piece runs under the heading "Tiny doses, big unknowns" and is labeled as opinion rather than a study or a trial report [1]. It describes microdosing as a practice aimed at cosmetic weight loss [1]. The article is illustrated with a photo of a woman using an injector pen to give herself a dose of Zepbound [1]. Dushay writes that she prescribes "only legitimate GLP-1 therapies to people with obesity and weight-related metabolic diseases" [1].
The article does not supply a dose range that would count as a microdose, a number for how many people are doing it, or data on how they fare over time. Those details have not been reported [1]. Because no standard definition exists, the term covers an undefined range, so two people describing a "microdose" may not mean the same amount [1].
Why it matters for patients
People who are curious about taking less than a prescribed dose have almost nothing to check against. The article states that the long-term evidence needed to judge the practice does not exist, and that the medical field has not settled on what a microdose is [1]. That leaves two gaps at once: no definition to compare experiences against, and no outcome data to weigh possible benefits against possible risks [1].
It also means the question is hard to answer in a doctor's office. A clinician who sticks to approved GLP-1 therapies, as Dushay says she does, has no evidence-based lower-dose protocol to work from [1]. And because the STAT piece is an opinion essay rather than new research, it argues from the absence of data rather than presenting results from a study of lower doses [1].
Patients may also hear the trend framed with more confidence than the evidence supports. According to the article, advertising and online promotion are part of what is driving interest, even though the supporting research is not there [1].
What happens next
The article does not describe any planned trial, regulatory action, or labeling change related to lower GLP-1 doses. Whether studies of microdosing are being organized, and how researchers would define a microdose if they run one, has not been reported [1].
Images from the sources
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.